Omega-3s are essential marine fats built into every cell membrane. The most dependable benefit is lowering blood triglycerides, with smaller effects on blood pressure and inflammatory joint symptoms. Signals for fewer heart attacks, better mood, and longer life are genuinely mixed. The main risk is a dose-related irregular heart rhythm at higher intakes. (Full Review)

Protocol

Standard Dose

1–2 g/day EPA+DHA

High-quality fish or algae oil; target omega-3 index 8–12%

Indication-Specific

2–4 g/day EPA+DHA

For high triglycerides; EPA-predominant ≥1 g/day EPA for mood support

Timing

With largest fatty meal

Improves absorption; split 2–4 g across two meals for tolerability

Time to effect

Triglyceride Reduction

4–8 weeks

Dose-dependent drop in blood triglycerides

Omega-3 Index & Membrane Benefits

3–4 months

Steady-state membrane levels; structural/membrane-mediated effects

Benefits

High: Triglyceride reduction

Medium: Reduced fatal coronary events & heart attack; blood pressure reduction; rheumatoid arthritis symptom relief

Low: Reduced depressive symptoms; slowed cognitive decline & dementia risk; reduced all-cause mortality

Speculative: Slowed biological aging; preserved muscle mass in aging

Contraindications

History of atrial fibrillation or significant arrhythmia

Scheduled surgery (pause high-dose ~7 days prior)

Full-dose anticoagulation

Fish or shellfish allergy

Key Interactions

Anticoagulants & antiplatelets (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel)

NSAIDs / aspirin (ibuprofen, naproxen)

Bleeding-risk supplements (vitamin E, garlic, Ginkgo biloba, nattokinase)

Blood-pressure-lowering drugs & supplements (potassium, magnesium, CoQ10)

Orlistat

Risk & Side Effects

High: Atrial fibrillation risk

Medium: Gastrointestinal side effects; increased bleeding tendency

Low: LDL-cholesterol increase; oxidation and rancidity exposure

Speculative: Prostate cancer risk; immune suppression at very high intake

Monitoring

Marker	Target	Why
Omega-3 Index (RBC EPA+DHA)	8–12%	Primary marker of omega-3 status and the target most tied to longevity data
Triglycerides	<90 mg/dL	Tracks the most reliable metabolic benefit of omega-3
LDL Cholesterol	<100 mg/dL (lower if high cardiovascular risk)	Detects any LDL rise from high-dose DHA products
hs-CRP	<1.0 mg/L	Gauges the anti-inflammatory response, a proposed pathway of benefit
Omega-6 : Omega-3 Ratio	<4:1	Reflects overall dietary fat balance influencing omega-3 effect

Cadence: Re-test at 3–4 months, then every 6–12 months; sooner if palpitations, unusual bleeding, or GI intolerance develop

Qualitative Assessment

Reduced joint stiffness or soreness in those with inflammatory or exercise-related discomfort
Improved mood or stress resilience, most relevant to EPA-predominant use
Better tolerance and adherence (no persistent fishy reflux or gastrointestinal upset)
Absence of new palpitations or irregular heartbeat

Omega-3 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment